Exploring Patient's Perspectives and Experiences After Start with Inhalation Maintenance Therapy: A Qualitative Theory-Based Study.
COPD
asthma
consultation
inhalation therapy
patient perspective
pharmaceutical care
pharmacy practice research
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
10
2019
accepted:
03
01
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
27
2
2020
Statut:
epublish
Résumé
Treatment of obstructive lung disease with inhalation therapy needs changes in patient behavior. Shortly after the start with inhaled corticosteroids (ICS) maintenance therapy, patients might be in need of additional pharmaceutical care, tailored to their individual needs. This study aimed to provide insight into patient behavior, goals and perceptions regarding their medical treatment at start with ICS therapy, by telephone interviews with ICS starters. Besides, this study investigated pharmacists' and patients' experiences with these interviews and opinions on the utility of this type of consultation for daily practice. Semi-structured telephone interviews were conducted by pharmacists with adult patients 2-3 weeks after starting ICS. The Theoretical Domain Framework (TDF) was used for data analysis and coding. Afterward, the patients and pharmacists were questioned about their experiences with the interview. Five pharmacists conducted interviews with 23 ICS starters. Except the domains "environmental context and resources", "optimism", and "reinforcement", the remaining 11 domains in the TDF were addressed in the interviews. The majority of patients defined personal goals, which mainly addressed disease or symptom control (clinical goals). Some patients showed a lack of knowledge regarding the clinical indication or therapy duration. Views on beneficial medication effects differed between patients. Some patients specifically mentioned concerns or anxiety about side effects. The interviewees described different perceptions on the necessity of a personalized routine for regular medication use. Patients and pharmacists both felt positive about an added value of these interviews for daily practice. Patient interviews shortly after start with ICS therapy revealed various perceptions and beliefs that might influence medication use and achievement of individual treatment goals. The patients appreciated the opportunity to ask questions and share their perspectives and needs with their pharmacist, and the pharmacists experienced that the interviews had added value.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment of obstructive lung disease with inhalation therapy needs changes in patient behavior. Shortly after the start with inhaled corticosteroids (ICS) maintenance therapy, patients might be in need of additional pharmaceutical care, tailored to their individual needs. This study aimed to provide insight into patient behavior, goals and perceptions regarding their medical treatment at start with ICS therapy, by telephone interviews with ICS starters. Besides, this study investigated pharmacists' and patients' experiences with these interviews and opinions on the utility of this type of consultation for daily practice.
METHODS
METHODS
Semi-structured telephone interviews were conducted by pharmacists with adult patients 2-3 weeks after starting ICS. The Theoretical Domain Framework (TDF) was used for data analysis and coding. Afterward, the patients and pharmacists were questioned about their experiences with the interview.
RESULTS
RESULTS
Five pharmacists conducted interviews with 23 ICS starters. Except the domains "environmental context and resources", "optimism", and "reinforcement", the remaining 11 domains in the TDF were addressed in the interviews. The majority of patients defined personal goals, which mainly addressed disease or symptom control (clinical goals). Some patients showed a lack of knowledge regarding the clinical indication or therapy duration. Views on beneficial medication effects differed between patients. Some patients specifically mentioned concerns or anxiety about side effects. The interviewees described different perceptions on the necessity of a personalized routine for regular medication use. Patients and pharmacists both felt positive about an added value of these interviews for daily practice.
CONCLUSION
CONCLUSIONS
Patient interviews shortly after start with ICS therapy revealed various perceptions and beliefs that might influence medication use and achievement of individual treatment goals. The patients appreciated the opportunity to ask questions and share their perspectives and needs with their pharmacist, and the pharmacists experienced that the interviews had added value.
Identifiants
pubmed: 32099338
doi: 10.2147/PPA.S234094
pii: 234094
pmc: PMC6996208
doi:
Types de publication
Journal Article
Langues
eng
Pagination
203-212Informations de copyright
© 2020 Kuipers et al.
Déclaration de conflit d'intérêts
Mrs Esther Kuipers and Dr Martina Teichert report grants from Royal Dutch Pharmacists Association and AstraZeneca, during the conduct of the study. The authors report no other conflicts of interest in this work.
Références
J Allergy Clin Immunol. 2007 Apr;119(4):811-6
pubmed: 17320942
J Res Pharm Pract. 2012 Oct;1(2):66-71
pubmed: 24991592
Patient Educ Couns. 2001 May;43(2):171-7
pubmed: 11369150
Patient Prefer Adherence. 2018 Sep 12;12:1777-1783
pubmed: 30254429
Patient Prefer Adherence. 2016 Apr 28;10:711-25
pubmed: 27175071
Front Pharmacol. 2013 Jul 25;4:91
pubmed: 23898295
Int J Pharm Pract. 2016 Feb;24(1):13-21
pubmed: 25988371
JAMA. 2003 Nov 5;290(17):2301-12
pubmed: 14600189
Implement Sci. 2012 Apr 24;7:37
pubmed: 22530986
Respir Med. 2018 Aug;141:180-189
pubmed: 30053965
Health Expect. 2004 Sep;7(3):235-45
pubmed: 15327462
Br J Clin Pharmacol. 2014 May;77(5):756-66
pubmed: 24117908
J Clin Pharm Ther. 2008 Feb;33(1):17-23
pubmed: 18211612
Respir Care. 2014 Nov;59(11):1716-25
pubmed: 24962222
Res Social Adm Pharm. 2019 May;15(5):514-520
pubmed: 29983262
Respir Med. 2016 Sep;118:22-30
pubmed: 27578467
J Eval Clin Pract. 2011 Feb;17(1):61-70
pubmed: 20807295
J Eval Clin Pract. 2011 Apr;17(2):381-3
pubmed: 21087372
Qual Saf Health Care. 2004 Jun;13(3):172-5
pubmed: 15175485
Respir Med. 2013 Sep;107(9):1346-55
pubmed: 23810267
Chron Respir Dis. 2019 Jan-Dec;16:1479973119855880
pubmed: 31195812
Br J Gen Pract. 2000 Apr;50(453):271-5
pubmed: 10897509
Soc Sci Med. 1997 Jul;45(2):189-201
pubmed: 9225407
Respir Med. 2013 Jan;107(1):37-46
pubmed: 23098685
Health Commun. 2016 Oct;31(10):1266-75
pubmed: 26940701
Pharm World Sci. 2004 Dec;26(6):328-32
pubmed: 15683102
J Asthma. 2010 Mar;47(2):198-201
pubmed: 20170329
Drugs. 2004;64(16):1779-800
pubmed: 15301562
Patient Prefer Adherence. 2016 Nov 02;10:2239-2254
pubmed: 27843303
BMC Res Notes. 2019 Feb 20;12(1):94
pubmed: 30786914
Implement Sci. 2017 Jun 21;12(1):77
pubmed: 28637486
Implement Sci. 2012 Apr 24;7:38
pubmed: 22531013
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
J Psychosom Res. 1999 Dec;47(6):555-67
pubmed: 10661603
Qual Health Res. 2017 Mar;27(4):591-608
pubmed: 27670770
Patient Educ Couns. 2015 Jul;98(7):843-8
pubmed: 25825256
Respir Med. 2010 Sep;104(9):1237-45
pubmed: 20472415
Expert Rev Clin Pharmacol. 2014 Sep;7(5):633-44
pubmed: 25088004
Qual Saf Health Care. 2005 Feb;14(1):26-33
pubmed: 15692000
Patient Educ Couns. 2011 Jun;83(3):417-22
pubmed: 21621948
J Allergy Clin Immunol. 2014 Dec;134(6):1260-1268.e3
pubmed: 25062783
Patient Educ Couns. 2003 Jan;49(1):13-8
pubmed: 12527148
Popul Health Manag. 2010 Aug;13(4):189-93
pubmed: 20735246
Patient Prefer Adherence. 2019 Jul 31;13:1325-1334
pubmed: 31534319
J Asthma. 2010 Apr;47(3):251-6
pubmed: 20394511